Comparative analysis on influence of simvastatin and fenofibrate on serum level of blood fat in patients ;with hyperlipidemia
ZHANG Jun
WEI Guo
Abstract：Objective To observe the clinical efficacy of simvastatin and fenofibrate on hyperlipidemia, and compare and analyze their influence on serum level of blood fat. Methods The patients with mixed hyperlipidemia (n=150) were randomly divided into simvastatin group, fenofibrate group and combining group (each n=50). The simvastatin group was given simvastatin (10 mg/d), fenofibrate group, fenofibrate (200 mg/d) and combining group, simvastatin (10 mg/d) and fenofibrate (200 mg/d). The changes of total cholesterol (TC), low-density lipoprotein (LDL-C), triglycerides (TG) and high-density lipoprotein (HDL-C) were detected 12 w before treatment and after treatment for 12 w, at the same time the changes of alanine aminotransferase (ALT), blood urea nitrogen (BUN), serum creatinine (Cr) and creatine kinase (CK) were monitored. Results After treatment for 12 w, TC, LDL-C, TG and HDL-C were ameliorated in 3 groups (P<0.05). The comparison between simvastatin group (TC:4.21±0.62 mmol/L, LDL-C:3.21±0.61 mmol/L) and fenofibrate group (TC:4.91±0.53 mmol/L, LDL-C:3.52±0.52 mmol/L) showed statistical difference (P<0.05). The comparison between simvastatin group and combining group (TC:4.31 ±0.63 mmol/L, LDL-C:3.22±0.61 mmol/L) showed no statistical difference (P>0.05), and comparison between fenofibrate group and combining group showed statistical difference (P<0.05). The comparison between simvastatin group (HDL-C:1.21±0.22 mmol/L, TG:2.91±0.62 mmol/L) and fenofibrate group (HDL-C;1.32±0.11mmol/L, TG:1.52±0.51 mmol/L) showed no statistical difference (P>0.05). The comparison between simvastatin group and combining group (HDL-C:1.41±0.21 mmol/L, TG:1.21±0.62 mmol/L) showed statistical difference (P<0.05) and comparison between fenofibrate group and combining group showed statistical difference (P<0.05). The difference in adverse reactions had no statistical significance among 3 groups (P>0.05). Conclusion The combined medication of simvastatin and fenofibrate has higher total effective rate than singly simvastatin or single fenofibrate in patients with mixed hyperlipidemia with higher safety, and adverse reactions is not increased.
Keywords：HyperlipidemiaSimvastatinFenofibrateSerum level of blood fat
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 804-806 )